CA2965196C - Preparations of meta-iodobenzylguanidine and precursors thereof - Google Patents

Preparations of meta-iodobenzylguanidine and precursors thereof Download PDF

Info

Publication number
CA2965196C
CA2965196C CA2965196A CA2965196A CA2965196C CA 2965196 C CA2965196 C CA 2965196C CA 2965196 A CA2965196 A CA 2965196A CA 2965196 A CA2965196 A CA 2965196A CA 2965196 C CA2965196 C CA 2965196C
Authority
CA
Canada
Prior art keywords
preparation
polymer
ppm
pharmaceutically acceptable
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2965196A
Other languages
English (en)
French (fr)
Other versions
CA2965196A1 (en
Inventor
Jason Moss
Machinani RAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Insight Pharmaceuticals Inc
Original Assignee
Molecular Insight Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Insight Pharmaceuticals Inc filed Critical Molecular Insight Pharmaceuticals Inc
Publication of CA2965196A1 publication Critical patent/CA2965196A1/en
Application granted granted Critical
Publication of CA2965196C publication Critical patent/CA2965196C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F230/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal
    • C08F230/04—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal containing a metal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C277/00—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C277/08—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups of substituted guanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/06—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
CA2965196A 2014-10-24 2015-10-23 Preparations of meta-iodobenzylguanidine and precursors thereof Active CA2965196C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462068598P 2014-10-24 2014-10-24
US62/068,598 2014-10-24
US201462069029P 2014-10-27 2014-10-27
US62/069,029 2014-10-27
PCT/US2015/057222 WO2016065322A1 (en) 2014-10-24 2015-10-23 Preparations of meta-iodobenzylguanidine and precursors thereof

Publications (2)

Publication Number Publication Date
CA2965196A1 CA2965196A1 (en) 2016-04-28
CA2965196C true CA2965196C (en) 2024-01-23

Family

ID=55174697

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2965196A Active CA2965196C (en) 2014-10-24 2015-10-23 Preparations of meta-iodobenzylguanidine and precursors thereof

Country Status (8)

Country Link
US (4) US20160115267A1 (enExample)
EP (2) EP3268052B1 (enExample)
JP (3) JP7078396B2 (enExample)
CN (1) CN107106710A (enExample)
AU (3) AU2015335599B2 (enExample)
CA (1) CA2965196C (enExample)
ES (1) ES2916550T3 (enExample)
WO (1) WO2016065322A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7078396B2 (ja) 2014-10-24 2022-05-31 モレキュラー インサイト ファーマシューティカルズ， インコーポレイテッド メタ－ヨードベンジルグアニジン及びその前駆体の調製物
CN109666039B (zh) * 2018-12-13 2020-12-25 山西大学 一种五核锡（ii）化合物及其制备方法和应用
TWI898889B (zh) * 2024-10-22 2025-09-21 國家原子能科技研究院 不含保護基之間三正丁基錫苯甲胍的製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4591630A (en) * 1981-07-30 1986-05-27 Ethicon, Inc. Annealed polydioxanone surgical device and method for producing the same
US5565185A (en) * 1994-07-20 1996-10-15 Merck Frosst Canada, Inc. Process for the preparation of radiolabeled meta-halobenzylguanidine
US6461585B1 (en) * 1998-10-02 2002-10-08 The University Of Western Ontario Preparation of radiolabelled haloaromatics via polymer-bound intermediates
US7273601B2 (en) * 2000-07-18 2007-09-25 The University Of Western Ontario Preparation of radiolabelled haloaromatics via polymer-bound intermediates
JP4846238B2 (ja) * 2002-10-18 2011-12-28 マクマスター ユニバーシティー 放射線標識した化合物の精製方法
GB0514087D0 (en) * 2005-07-11 2005-08-17 Ge Healthcare Ltd Stabilised radiopharmaceutical compositions
KR20170042373A (ko) 2010-05-11 2017-04-18 랜티우스 메디컬 이메징, 인크. 영상화제의 합성 및 사용을 위한 조성물, 방법 및 시스템
JP7078396B2 (ja) 2014-10-24 2022-05-31 モレキュラー インサイト ファーマシューティカルズ， インコーポレイテッド メタ－ヨードベンジルグアニジン及びその前駆体の調製物

Also Published As

Publication number Publication date
WO2016065322A1 (en) 2016-04-28
JP7078396B2 (ja) 2022-05-31
JP2017534742A (ja) 2017-11-24
US20230008878A1 (en) 2023-01-12
AU2015335599B2 (en) 2020-03-19
EP3888694A1 (en) 2021-10-06
AU2020204062B2 (en) 2022-07-07
US20240174782A1 (en) 2024-05-30
AU2020204062A1 (en) 2020-07-09
AU2015335599A1 (en) 2017-05-11
JP7186744B2 (ja) 2022-12-09
JP2022084797A (ja) 2022-06-07
HK1249425A1 (zh) 2018-11-02
US20190367653A1 (en) 2019-12-05
CA2965196A1 (en) 2016-04-28
JP7399996B2 (ja) 2023-12-18
JP2020143300A (ja) 2020-09-10
AU2020204062B9 (en) 2022-07-21
CN107106710A (zh) 2017-08-29
AU2022204262A1 (en) 2022-07-21
US11840592B2 (en) 2023-12-12
ES2916550T3 (es) 2022-07-01
EP3268052A1 (en) 2018-01-17
US11279784B2 (en) 2022-03-22
EP3268052B1 (en) 2021-06-23
US20160115267A1 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
US20240174782A1 (en) Preparations of meta-iodobenzylguanidine and precursors thereof
Huclier-Markai et al. Optimization of reaction conditions for the radiolabeling of DOTA and DOTA-peptide with 44m/44Sc and experimental evidence of the feasibility of an in vivo PET generator
CN102271716B (zh) 由甲苯磺酸酯前体合成18f-放射性标记的苯乙烯基吡啶及其稳定的药物组合物
AU2014308140B2 (en) Method for the quantification of 227Ac in 223Ra compositions
TWI905175B (zh) 放射性標記psma結合配位體的方法及其套組
Moustapha et al. Technetium-labeled danofloxacin complex as a model for infection imaging
Käkelä et al. Adventures in radiosynthesis of clinical grade [68 Ga] Ga-DOTA-Siglec-9
HK40061461A (en) Preparations of meta-iodobenzylguanidine and precursors thereof
HK1249425B (en) Preparations of meta-iodobenzylguanidine and precursors thereof
Venkatachalam et al. Synthesis of 18F‐radiolabeled diphenyl gallium dithiosemicarbazone using a novel halogen exchange method and in vivo biodistribution
RU2846977C1 (ru) Способы мечения радиоактивными изотопами psma-связывающих лигандов и наборы для их осуществления
WO2025030160A1 (en) Chelating compounds and methods of uses thereof
WO2026020383A1 (zh) Ark组合物及其在肿瘤诊断中的应用
WO2001070699A1 (en) Azure a analogues useful as probes in the diagnostic imaging for diseases due to accumulation of amyloid and compositions for diagnostic imaging containing the analogues
Greiser et al. Investigations on the Ga (III) complex of EOB-DTPA and its 68Ga radiolabeled analogue
Varlamova et al. Synthesis and Study of Norfloxacin Labeled with Technecium-99m as a Potential Imaging Agent of Bacterial Inflammations
Ferris Zirconium-89 Complexes for Cell Tracking with Positron Emission Tomography

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201001

EEER Examination request

Effective date: 20201001

EEER Examination request

Effective date: 20201001

EEER Examination request

Effective date: 20201001

EEER Examination request

Effective date: 20201001

EEER Examination request

Effective date: 20201001

EEER Examination request

Effective date: 20201001

EEER Examination request

Effective date: 20201001

EEER Examination request

Effective date: 20201001

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241017

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241017